ORKA-002 for Hidradenitis Suppurativa
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
Are You a Good Fit for This Trial?
This trial is for adults with moderate-to-severe hidradenitis suppurativa (HS) who have had symptoms for at least 6 months, HS in two or more body areas (with one being advanced), and haven't improved with antibiotics or can't take them. People with other active skin diseases or autoimmune conditions can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction Period
Participants receive ORKA-002 or placebo every 4 weeks for 12 weeks during a double-blind induction period
Maintenance Period
Participants receive ORKA-002 every 12 weeks during an open-label maintenance period
Post-Treatment Follow-Up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ORKA-002
Trial Overview
The study compares a new drug called ORKA-002 to a placebo (inactive treatment) in people with moderate-to-severe HS. Participants are randomly assigned to receive either the real drug or placebo without knowing which they get.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will receive Placebo per protocol Induction regimen.
Participants will receive ORKA-002 per protocol Induction regimen.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oruka Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.